Ashwagandha for Mood and Depression: BDNF, Cortisol Reduction and the Clinical Evidence

Ashwagandha's role in mood and depression support is most accurately framed as targeting the cortisol-depression pathway — the mechanism by which chronic stress and HPA overactivation produces and maintains depressive states. Where pharmaceutical antidepressants primarily target monoamine reuptake, ashwagandha targets the upstream stress-biology that drives a substantial proportion of depressive presentations. In populations where depression is stress-precipitated, cortisol is elevated, and sleep is disrupted — which describes the majority of community depression cases — ashwagandha addresses multiple biological drivers simultaneously through its HPA axis modulation, BDNF restoration, and sleep quality improvement.

The Cortisol-Depression Connection

The mechanisms linking cortisol elevation to depression are well-established:

• Hippocampal neurodegeneration: Sustained cortisol elevation reduces hippocampal BDNF expression, shrinks hippocampal volume (documented in major depression by MRI), and impairs hippocampal neurogenesis — structural brain changes that maintain depressive states and impair emotional regulation
• Serotonin suppression: Cortisol activates IDO (indoleamine 2,3-dioxygenase) — diverting tryptophan from serotonin synthesis toward the kynurenine pathway, reducing serotonin availability
• Sleep disruption: Elevated evening cortisol suppresses melatonin, reduces slow-wave and REM sleep, and impairs the overnight emotional processing that prevents daily stressors from accumulating into sustained mood disorders
• Inflammatory activation: Chronic cortisol paradoxically drives neuroinflammation through glucocorticoid receptor desensitisation — contributing to the inflammatory subtype of depression

Ashwagandha addresses all four of these mechanisms through HPA axis normalisation — making it mechanistically appropriate for the stress-precipitated, cortisol-elevated depression phenotype that standard antidepressants often address incompletely.

Research: Depression Scores in RCTs

Multiple ashwagandha RCTs have measured depression alongside anxiety and stress using validated scales:

• Chandrasekhar et al. (2012): GHQ-28 total score (which includes depression subscale) significantly reduced with KSM-66 — 71.6% improvement vs 11.6% placebo
• Lopresti et al. (2019): DASS-21 depression subscale significantly reduced with 240mg KSM-66 over 60 days — alongside significant cortisol normalisation
• Choudhary et al. (2017): BDI (Beck Depression Inventory) significantly improved with 300mg twice daily over 8 weeks in cognitively and psychologically stressed adults

The pattern across studies is consistent: ashwagandha produces significant depression score improvements in populations where stress and elevated cortisol are primary drivers — which is the typical community presentation of mild-to-moderate depression.

Mechanism: BDNF Restoration

Ashwagandha increases BDNF expression in the hippocampus and prefrontal cortex through multiple mechanisms: direct withanolide effects on BDNF gene transcription, cortisol reduction (removing the primary suppressor of hippocampal BDNF), and improved sleep quality (deep sleep is the primary window for hippocampal BDNF production and consolidation). A clinical study found ashwagandha supplementation significantly increased serum BDNF levels compared to placebo, correlating with mood score improvements.

Mechanism: MAO Inhibition and Monoamine Enhancement

Withaferin A and withanolide D have demonstrated MAO-A inhibitory activity in preclinical studies — reducing serotonin and norepinephrine degradation and increasing monoamine availability in synapses. This provides an additional antidepressant mechanism beyond the cortisol/BDNF pathway — potentially explaining why ashwagandha produces mood improvements that extend beyond what cortisol reduction alone would predict.

Ashwagandha as an Antidepressant Complement

Ashwagandha's cortisol-reducing and sleep-improving effects address biological factors that impair antidepressant response — elevated cortisol reduces SSRI effectiveness by suppressing serotonin synthesis, and sleep disruption impairs antidepressant consolidation. Several studies have examined ashwagandha as an adjunct to antidepressant therapy and found it improves response rates in partial responders — consistent with its addressing different biological targets than monoamine-reuptake inhibitors.

Dosage for Mood Support

• Dose: 300-600mg KSM-66 daily. Split dosing (morning + evening) is preferable for mood applications — morning dose for daytime cortisol management, evening for sleep quality
• Evening dose timing: 60-90 minutes before sleep for maximum sleep quality benefit
• Duration: 4-8 weeks for meaningful mood effects — cortisol normalisation and BDNF restoration require sustained supplementation
• Note: Ashwagandha complements rather than replaces professional mental health assessment. Always consult a healthcare professional for clinical depression.